Role of the angiotensin II type 2 receptor gene (+1675G/A) polymorphism on left ventricular hypertrophy and geometry in treated hypertensive patients

Journal of Hypertension

Volumn 28, Issue 6, 2010, Pages 1221-1229

  Huber, Matthias ^a   Völler, Heinz ^a,c   Jakob, Stefanie ^a   Reibis, Rona ^a,c   Do, Van ^a   Bolbrinker, Juliane ^a   Zergibel, Irina ^a   Schmieder, Roland E ^d   Treszl, Andras ^e   Wegscheider, Karl ^e   Kreutz, Reinhold ^a,b  

^a Inst Clin Pharmacol and Toxicol   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Klinik Am See   (Norway)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiotensin; Angiotensin II type 2 receptor; Genetics; Heart; Hypertension; Hypertrophy

Indexed keywords

ADENINE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GUANINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HUMAN; ISCHEMIC HEART DISEASE; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSE PRESSURE; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; X CHROMOSOME;

EID: 77952482163     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833aa356     Document Type: Article

References (60)

1. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117:568-575.
2. Muiesan ML, Salvetti M, Paini A, Monteduro C, Galbassini G, Bonzi B, et al. Inappropriate left ventricular mass changes during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2007; 49:1077-1083.
3. Susic D, Frohlich ED. The aging hypertensive heart: a brief update. Nat Clin Pract Cardiovasc Med 2008; 5:104-110.
4. Arnett DK, de las FL, Broeckel U. Genes for left ventricular hypertrophy. Curr Hypertens Rep 2004; 6:36-41.
5. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004; 43:731-738.
6. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008; 21:500-508.
7. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
8. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008; 26:1477-1486.
9. Paul M, Poyan MA, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86:747-803.
10. Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007; 29:1803-1824.
11. Siegel AK, Planert M, Rademacher S, Mehr AP, Kossmehl P, Wehland M, et al. Genetic loci contribute to the progression of vascular and cardiac hypertrophy in salt-sensitive spontaneous hypertension. Arterioscler Thromb Vasc Biol 2003; 23:1211-1217.
12. Castellano M, Muiesan ML, Beschi M, Rizzoni D, Cinelli A, Salvetti M, et al. Angiotensin II type 1 receptor A/C1166 polymorphism. Relationships with blood pressure and cardiovascular structure. Hypertension 1996; 28:1076-1080.
13. Danser AH, Schunkert H. Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur J Pharmacol 2000; 410:303-316.
14. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332:706-711.
15. van Berlo JH, Pinto YM. Polymorphisms in the RAS and cardiac function. Int J Biochem Cell Biol 2003; 35:932-943.
16. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002; 20:657-663.
17. Kreutz R. Pharmacogenetics of antihypertensive drug response. Curr Hypertens Rep 2004; 6:15-20.
18. Schmieder RE, Erdmann J, Delles C, Jacobi J, Fleck E, Hilgers K, et al. Effect of the angiotensin II type 2-receptor gene (\+1675G/A) on left ventricular structure in humans. J Am Coll Cardiol 2001; 37:175-182.
19. Alfakih K, Maqbool A, Sivananthan M, Walters K, Bainbridge G, Ridgway J, et al. Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (1332 G/A) in patients with systemic hypertension. Hypertension 2004; 43:1189-1194.
20. Herrmann SM, Nicaud V, Schmidt-Petersen K, Pfeifer J, Erdmann J, McDonagh T, et al. Angiotensin II type 2 receptor gene polymorphism and cardiovascular phenotypes: the GLAECO and GLAOLD studies. Eur J Heart Fail 2002; 4:707-712.
21. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events The MESA (Multi-Ethnic Study of Atherosclerosis) Study. J Am Coll Cardiol 2008; 52:2148-2155.
22. Tocci G, Sciarretta S, Facciolo C, Volpe M. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Rev Cardiovasc Ther 2007; 5:767-776.
23. -1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17:151-183.
24. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147.
25. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
26. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
27. Feigenbaum H. Echocardiography. Philadelphia: Lea & Febinger; 1994; pp. 138-140.
28. de SG, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens 2005; 18 (2 Pt 1):191-196.
29. de SG, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25:1056-1062.
30. Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, et al. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension 2008; 52:279-286.
31. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004; 17:1086-1119.
32. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
33. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
34. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT(2) receptors: functional relevance in cardiovascular disease. Pharmacol Ther 2008; 120: 292-316.
35. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003; 12:70-88.
36. Steckelings UM, Kaschina E, Unger T. The AT2 receptor: a matter of love and hate. Peptides 2005; 26:1401-1409.
37. Volpe M, Musumeci B, De PP, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003; 21:1429-1443.
38. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001; 281:H2337-H2365.
39. Martin MM, Elton TS. The sequence and genomic organization of the human type 2 angiotensin II receptor. Biochem Biophys Res Commun 1995; 209:554-562.
40. Nishimura H, Yerkes E, Hohenfellner K, Miyazaki Y, Ma J, Hunley TE, et al. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell 1999; 3:1-10.
41. Jones A, Dhamrait SS, Payne JR, Hawe E, Li P, Toor IS, et al. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. Hypertension 2003; 42:500-506.
42. Alfakih K, Lawrance RA, Maqbool A, Walters K, Ball SG, Balmforth AJ, et al. The clinical significance of a common, functional, X-linked angiotensin II type 2-receptor gene polymorphism (1332 G/A) in a cohort of 509 families with premature coronary artery disease. Eur Heart J 2005; 26:584-589.
43. Alfakih K, Brown B, Lawrance RA, Warburton P, Maqbool A, Walters K, et al. Effect of a common X-linked angiotensin II type 2-receptor gene polymorphism (1332 G/A) on the occurrence of premature myocardial infarction and stenotic atherosclerosis requiring revascularization. Atherosclerosis 2007; 195:e32-e38.
44. Kuznetsova T, Staessen JA, Thijs L, Kunath C, Olszanecka A, Ryabikov A, et al. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation 2004; 110:2644-2650.
45. Ott C, Titze SI, Schwarz TK, Kreutz R, Hilgers KF, Schmidt BM, et al. High sodium intake modulates left ventricular mass in patients with G expression of\+1675G/A angiotensin II receptor type 2 gene. J Hypertens 2007; 25:1627-1632.
46. Warnecke C, Mugrauer P, Surder D, Erdmann J, Schubert C, Regitz-Zagrosek V. Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing. Am J Physiol Regul Integr Comp Physiol 2005; 289:R1729-R1735.
47. D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 2005; 46:1347-1354.
48. Senbonmatsu T, Ichihara S, Price E Jr, Gaffney FA, Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 2000; 106:R1-R5.
49. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001; 104:346-351.
50. Reudelhuber TL. The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 2005; 46:1261-1262.
51. Wharton J, Morgan K, Rutherford RA, Catravas JD, Chester A, Whitehead BF, et al. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther 1998; 284:323-336.
52. Alfakih K, Reid S, Jones T, Sivananthan M. Assessment of ventricular function and mass by cardiac magnetic resonance imaging. Eur Radiol 2004; 14:1813-1822. (Pubitemid 39386630)
53. Schmieder RE, Langenfeld MR, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996; 94:1304-1309.
54. Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol 1996; 77:8C-16C.
55. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996; 28:635-640.
56. Booz GW. Cardiac angiotensin AT2 receptor: what exactly does it do? Hypertension 2004; 43:1162-1163.
57. Carey RM. Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 2005; 14:67-71.
58. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 2008; 120:292-316.
59. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008; 118:2523-2532.
60. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 2003; 140:809-824.